cardiovascular testosterone

Reference: Clinical Endocrinology. 2018;1–8. Summary Objective: A label change in testosterone (T) products in March 2015 followed a highly publicized FDA advisory committee meeting in September 2014. Changes included a warning of possible increased cardiovascular (CV) risks and...